Quality System
Lixin Honor:

Lixin Pharmaceutical was approved by U.S. Food and Drug Administration (FDA) in 2010, and had a review with zero defect in 2015.

Lixin Pharmaceutical was approved by European Directorate for the Quality of Medicines (EDQM), European Medicines Agency (EMA) in Oct, 2016.

A number of products receive certificates of GMP by China Food and Drug Administration (CFDA)

About Us
Since established in 2000, Suzhou Lixin Pharmaceutical CO., Ltd. has been aimed at develop the global normative dominant market of APIs and advanced intermediates, driven by technological innovation, taken the path of sustainable development, and gradually form a raw materials products system including anti-tumor, cardiovascular, anti-platelet and treatment of senile dementia and other areas. Lixin Pharmaceutical has already been the high-quality supplier of many global pharmaceutical companies, and also established long-term relationship with a number of well-known domestic and foreign pharmaceutical companies to achieve win-win cooperation.
  R&D
NEWS    LiXin News
Image

我公司氢氯噻嗪、吲达帕胺通过CEP认证

我公司氢氯噻嗪、吲达帕胺通过CEP认证...

Image

苏州立新制药有限公司抗肿瘤及心血管原料药技改项目 自查评估报告公示

苏州立新制药有限公司抗肿瘤及心血管原料药技改项目 自查评估报告…...

Image

立新制药顺利通过第二次FDA检查

立新制药顺利通过第二次FDA检查...